000			02806nam a22003737a 4500
008			191010s20192019 xxu||||| |||| 00| 0 eng d
022			_a2228-7523
024			_a10.5812/aapm.89990 [doi]
024			_aPMC6712359 [pmc]
040			_aOvid MEDLINE(R)
099			_a31497519
245			_aEfficacy of Methotrexate on Pain Severity Reduction and Improvement of Quality of Life in Patients with Moderate to Severe Knee Osteoarthritis.
251			_aAnesthesiology & Pain Medicine. 9(3):e89990, 2019 Jun.
252			_aAnesth. pain med.. 9(3):e89990, 2019 Jun.
253			_aAnesthesiology and pain medicine
260			_c2019
260			_fFY2019
265			_sepublish
266			_d2019-10-10
520			_aBackground: Knee osteoarthritis (OA) leads to low quality of life due to pain and limitation in daily activities. Recent studies indicated that Methotrexate (MTX) could reduce pain due to its anti-inflammatory effects.
520			_aConclusions: Treatment of moderate to severe knee OA with MTX could reduce pain severity and improve functional status and quality of life in OA patients.
520			_aMethods: In this randomized clinical trial, 100 patients with moderate to severe knee OA were allocated to receive MTX (n = 50) 7.5 mg weekly to be increased to 15 mg weekly after first months or placebo (n = 50) for six months. Pain severity was measured using the numerical rating scale (NRS), so was functional status by Western Ontario and McMaster Universities Arthritis Index (WOMAC) and quality of life by SF-12 questionnaire before the treatment, and three months and six months after the intervention. The results were compared between the groups subsequently. Nine patients from the MTX group were excluded due to the use of corticosteroids during the treatment period.
520			_aObjectives: In this study, the researchers aimed at evaluating the efficacy of MTX in pain control and improvement of quality of life in patients with moderate to severe knee OA.
520			_aResults: The MTX group compared to the placebo group had significant improvement in pain severity and quality of life during six months and WOMAC parameters at three and six months after the intervention. The need for NSAIDS was slightly higher in the placebo group with no significant difference (22% versus 36%, P = 0.14). The MTX adverse effects were not observed.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aMedicine/Internal Medicine
657			_aJournal Article
700			_aHemmati, Mehdi
790			_aEnteshari-Moghaddam A, Habibzadeh A, Hemmati M, Isazadehfar K
856			_uhttps://dx.doi.org/10.5812/aapm.89990 _zhttps://dx.doi.org/10.5812/aapm.89990
942			_cART _dArticle
999			_c4627 _d4627